Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed non-small cell lung cancer

Locally advanced (stage IIIB) or metastatic (stage IV) disease
Inoperable disease

Relapsed or refractory disease

Received 1, and only 1, prior chemotherapy regimen for locally advanced or metastatic disease
Measurable or evaluable disease
No symptomatic or inadequately treated brain metastases
No CNS disease

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

Karnofsky 70-100%

Life expectancy

More than 3 months

Hematopoietic

Platelet count greater than 100,000/mm^3
Hemoglobin greater than 8.0 g/dL
Absolute neutrophil count greater than 1,500/mm^3

Hepatic

AST and ALT less than 3 times upper limit of normal (ULN)
Bilirubin less than 1.5 times ULN
Hepatitis B surface antigen negative
Hepatitis C negative

Renal

Creatinine less than 1.8 mg/dL

Cardiovascular

No myocardial infarction within the past 6 months
No New York Heart Association class III or IV heart failure
No uncontrolled angina
No severe uncontrolled ventricular arrhythmias
No electrocardiographic evidence of acute ischemia or active conduction system abnormalities
No poorly controlled hypertension

Immunologic

No active systemic infection requiring treatment
No prior allergic reaction attributable to compounds containing boron or mannitol
HIV negative

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier contraception
No peripheral neuropathy grade 2 or greater
No diabetes mellitus
No other serious medical or psychiatric condition that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

More than 6 weeks since prior monoclonal antibody therapy
No concurrent routine use of colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF])
No concurrent immunotherapy

Chemotherapy

See Disease Characteristics
More than 4 weeks since prior chemotherapy

No prior docetaxel

Prior paclitaxel allowed
No other concurrent chemotherapy

Endocrine therapy

No concurrent corticosteroids (e.g., prednisone or prednisolone) except dexamethasone as premedication

Radiotherapy

More than 4 weeks since prior radiotherapy
No concurrent radiotherapy

Surgery

More than 4 weeks since prior major surgery
No concurrent surgery for cancer management or treatment

Other

More than 5 years since prior treatment for any other cancer except basal cell skin cancer or carcinoma in situ of the cervix
More than 4 weeks since prior investigational agents
No prior bortezomib
No other concurrent investigational agents
No other concurrent clinical research study participation
No other concurrent antineoplastic therapy
No concurrent routine use of anti-inflammatory drugs, including cyclo-oxygenase inhibitors (e.g., celecoxib or rofecoxib)